OVID

Ovid is a clinical-stage biopharma developing small-molecule brain-disorder drugs, and its financials confirm it is pre-commercial: the MD&A states just one program is in human trials with a second only 'expected to begin a clinical trial in the first half of 2026.' The $7.25M of FY2025 'revenue' is royalty/licensing income, not product sales — and the five-year history exposes how non-durable it is (FY2021 $208M was the one-time $196M Takeda RLT upfront, collapsing to $392K in FY2023). On that basis the P/S of 48.9 and the -585% operating margin are not meaningful valuation signals; they simply reflect that there is no commercial engine yet. Operating loss was -$42.4M and operating cash burn -$38.3M, with the FY2025 net loss of -$17.4M flattered by a $21.0M non-cash fair-value gain on a long-term equity investment — the underlying cash outflow is what matters.

The balance sheet is the one genuine positive: liabilities/equity of just 0.16x, $131M equity, and per the MD&A $90.4M in cash, equivalents and marketable securities (note XBRL cash & equivalents alone fell 50% to $13.2M as funds moved into U.S. treasuries). Against ~$38M annual burn that is roughly two years of runway — but it was bought with heavy dilution: shares outstanding rose 85.5% to 132M, and the October 2025 private placement layered on 57,722 Series B preferred shares plus Series A warrants for 38,481,325 shares and Series B warrants for 28,861,000 shares. That ~67M-share warrant overhang against a 132M base is a structural weight on the stock, and management explicitly expects expenses to 'increase substantially' and losses to continue 'for at least the next several years.'